Status:
COMPLETED
Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML)
Lead Sponsor:
Eisai Inc.
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
60+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to estimate the rate of complete remission, as well as overall survival, in older patients with Acute Myeloid Leukemia (AML).
Eligibility Criteria
Inclusion
- A diagnosis of AML or transformed from myelodysplastic syndrome (MDS) within 2 weeks of study enrollment.
- Ineligible to receive intensive chemotherapy for their disease.
- Have not received any chemotherapy within 4 weeks of study enrollment and must have recovered from any treatment-related toxicities.
Exclusion
- Received previous treatment for AML.
- Previously received Vidaza.
- Received any other investigational agents within 30 days of first dose of study drug.
- Uncontrolled intercurrent illness.
- Had radiotherapy within 14 days prior to study enrollment.
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT00358644
Start Date
March 1 2005
End Date
December 1 2008
Last Update
May 20 2013
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Duarte, California, United States, 91010
2
Los Angeles, California, United States, 90095-1678
3
St Louis, Missouri, United States, 63110